CTOs on the Move

Mirna Therapeutics

www.mirnarx.com

 
Mirna Therapeutics, Inc. (Mirna) is a biotechnology research and development company focused on miRNA-directed oncology therapies. Featuring world-class research capabilities, a strong understanding of miRNA and cancer biology, and a broad IP portfolio, Mirna Therapeutics is well-positioned to capitalize on the emerging field of miRNA-based therapeutics.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.mirnarx.com
  • 2150 Woodward St. Suite 100
    Austin, TX USA 78744
  • Phone: 512.901.0900

Executives

Name Title Contact Details

Funding

Mirna Therapeutics raised $42M on 05/01/2015

Similar Companies

Semler Research Center Pvt.

Semler Research Center Pvt. is a North Hollywood, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alsius Corporation

Alsius Corporation (Alsius) is a commercial-stage medical device company that develops, manufactures and sells products to precisely control patient temperature in hospital critical care settings. The Company operates through its wholly owned subsidiary,

Kurome Therapeutics

Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms.

Principia Biopharma

Principia Biopharma is a privately-held biopharmaceutical company focused on the discovery and development of best-in-class small molecule drugs for autoimmune diseases and cancer. The company uses its proprietary technology, licensed from the University of California San Francisco, to enable a new approach to making small molecules that are potent, safe and have antibody-like specificity. Principia raised $40 million in a Series A round of financing from a leading group of healthcare investors, including New Leaf Venture Partners, OrbiMed Advisors, Morgenthaler Ventures, SROne and Mission Bay Capital.

Chi Botanic

Changing how we grow with plant cell cultures.